High-yield points
- Overall: pLGG is a MAPK pathway disease; a driver is found in 84% .
- Fusions: behave indolently.
- BRAF V600E: worse, especially with CDKN2A deletion .
- Key molecular markers:
- Ganglioglioma: BRAF V600E in about 20–40% .
- PXA: BRAF V600E in about 65% .
- DNET: FGFR1, and never V600E .
- PLNTY: FGFR2/3 or V600E, CD34-positive, calcified, temporal .
- Angiocentric glioma: MYB–QKI .
- Tumor control: GTR is the main predictor of PFS. After surgery alone, OS is about 96–97% .
- Seizure control:
- Overall: about 80% Engel I.
- Predictors: GTR (OR 5.3) and epilepsy of 1 year or less (OR 9.5) .
- Practice: operate early and remove the whole lesion plus adjacent dysplasia.
- LITT: an option for deep or eloquent and recurrent LGG :
- Effect: tumor volume falls in about 80%, and 90% need no further surgery.
- Risk: permanent deficits in about 5–6%. Complications rise 14% per cm³ of ablation.
- Biopsy first, and keep the ablation volume small.
- Targeted therapy:
- BRAF V600: dabrafenib + trametinib beat carboplatin/vincristine first line (47% vs. 11% response) .
- MEK inhibitors: active in BRAF-altered and NF1 tumors .
- Avoid radiation in hemispheric LGG. It adds no survival benefit, and all three malignant transformations in one series followed it .
Landmark papers
- COG natural-history study (Wisoff et al., Neurosurgery 2011): 518 evaluable low-grade gliomas managed by surgery alone. 5- and 8-year OS were 97% and 96% and PFS 80% and 78%, and GTR without residual was the dominant predictor of PFS .
- Dabrafenib plus trametinib (Bouffet et al., N Engl J Med 2023): a randomized phase 2 trial (110 patients) of first-line therapy. Response was 47% vs 11% with carboplatin/vincristine, and median PFS 20.1 vs 7.4 months .
Pediatric low-grade gliomas (pLGG) are the most common CNS tumors of childhood .
- Most are driven by a single RAS/MAPK alteration: a driver is found in 84% .
- Hemispheric and cortical tumors often present with epilepsy. Seizure control is as important an outcome as tumor control.
- Tumors are the second most common lesion in epilepsy surgery after focal cortical dysplasia in children, and are mainly gangliogliomas .
WHO 2021 framework
- Three families hold pLGG and glioneuronal tumors :
1. Pediatric-type diffuse low-grade gliomas: - diffuse astrocytoma, MYB- or MYBL1-altered; - angiocentric glioma; - PLNTY; - diffuse LGG, MAPK-altered. 2. Circumscribed astrocytic gliomas: - pilocytic astrocytoma (see its own topic); - pleomorphic xanthoastrocytoma (PXA); - SEGA. 3. Glioneuronal and neuronal tumors: - ganglioglioma; - DNET; - DIG/DIA; - myxoid glioneuronal tumor; - MVNT; - DGONC; - others.
- The six types new in 2021 :
- MYB/MYBL1-altered diffuse astrocytoma;
- PLNTY;
- diffuse LGG, MAPK-altered;
- DGONC;
- myxoid glioneuronal tumor;
- MVNT.
- Molecular class predicts behavior (more than 1,000 pLGG) :
- Rearrangement-driven tumors (fusions):
- present younger;
- are mostly grade 1;
- rarely progress or cause death.
- SNV-driven tumors (e.g., BRAF V600E) do worse.
The main entities
- Ganglioglioma:
- Epilepsy: up to 40% of lesional epilepsy .
- BRAF V600E :
- Frequency: found in 18% of 77 tumors in one series, and 38% of 47 pediatric tumors in another.
- Prognosis: in children, it predicts shorter recurrence-free survival .
- Recurrence: 28% recurred in a pediatric series of 53 .
- DNET:
- Clinical picture: a benign, cortex-based tumor with drug-resistant epilepsy .
- Molecular:
- FGFR1 alterations in 58% of centrally confirmed DNETs, mainly tyrosine-kinase domain duplication.
- BRAF V600E in none .
- Familial multinodular DNET with a germline FGFR1 mutation has been described .
- If a "DNET" carries BRAF V600E, reconsider the diagnosis. Among cases not confirmed as DNET on review, 22.6% had V600E .
- Associated cortical dysplasia: adjacent focal cortical dysplasia was present in 52% of one surgical series .
- PLNTY (polymorphous low-grade neuroepithelial tumor of the young):
- Pathology: an epileptogenic tumor with oligodendroglioma-like components, infiltrative growth and intense CD34 staining .
- Molecular: BRAF or FGFR2/FGFR3 alterations .
- Case series (13) :
- Presentation: temporal in 9 and seizures in 9 of 12.
- MAPK activation in all.
- Age splits the driver:
- fusions (mainly FGFR2) in the youngest;
- BRAF V600E at 17 years and older.
- Pleomorphic xanthoastrocytoma (PXA):
- BRAF V600E in about 65% .
- Long-term series (74 patients, 31 pediatric) :
- Anaplasia worsens survival (mitoses 5 or more per 10 HPF, or necrosis).
- BRAF V600E was associated with longer OS.
- Early recurrence or death was linked to anaplasia and non-GTR.
- Angiocentric glioma:
- Driver: a MYB–QKI fusion is the specific single driver event. It was found in angiocentric gliomas within a 249-tumor pLGG cohort .
- Classification: a pediatric-type diffuse LGG under WHO 2021 .
Surgery: tumor control
- COG prospective natural-history study (518 evaluable LGG managed by surgery alone) :
- Survival: 5- and 8-year OS 97% and 96%, and PFS 80% and 78%.
- GTR without residual was the dominant predictor of PFS. With limited residual, 56% were progression-free at 5 years.
- Take-away: Aim for GTR whenever it can be done without unacceptable deficits.
- Hemispheric LGG (71 children) :
- Survival: OS 95%, 93% and 85% at 5, 10 and 20 years.
- Extent of resection was the strongest predictor of OS and PFS.
- Radiotherapy did not improve survival. All three malignant transformations followed prior radiotherapy.
Surgery: seizure control
- Glioneuronal tumors overall (910 patients, ganglioglioma and DNET) :
- Overall: 80% Engel I.
- GTR vs. subtotal: OR 5.34.
- Epilepsy duration of 1 year or less: OR 9.48.
- Secondarily generalized seizures predicted worse outcome (OR 0.40).
- Extended temporal resection (hippocampectomy and/or corticectomy) added benefit.
- No difference by age, temporal vs. extratemporal site, ganglioglioma vs. DNET, or use of electrocorticography.
- Ganglioglioma (review) :
- Seizure freedom: 63–100%, and durable.
- Better with: greater resection, shorter epilepsy and younger age.
- DNET:
- Review of 29 studies :
- Seizure freedom: median 86%.
- GTR rate: median 79%.
- Greater resection was linked to seizure freedom.
- UCSF series of 50 :
- Engel I: 86% at 1 year and 85% at 5 years.
- Complete or extended resection predicted freedom, as did extratemporal location.
- ECoG: with extralesional spikes, extended resection gave 94% seizure freedom.
- Tumor progression occurred only after subtotal resection.
- Practical principles:
- Operate early.
- Aim for complete lesionectomy.
- Temporal tumors: consider extended resection including mesial structures.
- Include adjacent dysplastic cortex when it is present .
Laser interstitial thermal therapy (LITT)
- What it is: MR-guided stereotactic laser ablation (also called SLA or MRgLITT). Through a twist-drill hole, an MR-thermometry-monitored laser fiber cytoreduces a tumor without a craniotomy.
- Its niche in pLGG: small-to-moderate tumors that are deep or eloquent, where open resection carries high morbidity (thalamus, insula, mesial temporal, periventricular). Also recurrent or residual tumor after prior surgery .
- Evidence (retrospective only):
- Multi-institutional series (17 North American centers, 86 children; 76 low-grade, 10 high-grade tumors) :
- Effect: tumor volume fell in 80.6% at a median of 18 months.
- No further treatment needed: 90.4% needed no further surgery and 86.7% no adjuvant therapy.
- High-grade tumors were more likely to stay the same size or grow (OR 7.49).
- Complications: 29 in 23 patients:
- transient deficits, 11;
- permanent deficits, 5;
- hydrocephalus, 4;
- hemorrhage, 2;
- symptomatic edema, 2;
- deaths, 2.
- Complication risk rose 14% per 1 cm³ of ablation volume.
- Meta-analysis of pediatric CNS tumors (24 studies) :
- Pooled retrospective cohorts (97 patients; mostly pilocytic astrocytoma and SEGA):
- Mass reduction: 68.8%.
- Deficits: transient 12.1%, permanent 6.0%.
- Mortality: 2.6%.
- Case series (67 patients; 61% eloquent): hospital stay was 3 days or less in 92.7%.
- Greater extent of ablation meant less secondary surgery and better disease outcome.
- Early single-center experience (9 LGGs, 6 previously operated) :
- Results: 8 of 9 needed no further therapy.
- Complication: significant post-ablation edema, in a midbrain–thalamic tumor.
- Practical points:
- Get tissue first. Molecular classification (BRAF, FGFR, MYB, etc.) now drives prognosis and targeted therapy, so a stereotactic biopsy through the same trajectory before ablation is standard .
- Keep the ablation volume as small as needed. Expect transient perilesional edema and plan steroids, especially in the thalamus and brainstem .
- Ablation is cytoreduction, not resection. There is no specimen margin, and response is judged on follow-up MRI.
- For epilepsy-associated tumors (ganglioglioma, DNET): LITT is attractive for deep mesial temporal or insular lesions. But pediatric seizure-outcome data are limited to small series and case reports. Open lesionectomy remains the standard against which LITT is measured .
Medical and targeted therapy
- When needed: for unresectable, progressive or recurrent tumors.
- BRAF V600E pLGG responds poorly to chemotherapy and radiation :
- 10-year PFS: 27% vs. 60% for wild-type.
- Independent adverse factors: CDKN2A deletion and incomplete resection.
- Dabrafenib + trametinib, first line, randomized phase 2 (110 patients) :
- Response: 47% vs. 11% with carboplatin/vincristine.
- Median PFS: 20.1 vs. 7.4 months (HR 0.31).
- Grade 3 or worse adverse events: less often (47% vs. 94%).
- Selumetinib (MEK inhibitor), phase 2, recurrent disease :
- Sustained partial response:
- 36% in BRAF-altered pilocytic astrocytoma;
- 40% in NF1-associated LGG.
- Phase 3 trials vs. chemotherapy followed.
Related topics
- Pilocytic Astrocytoma: the commonest pediatric glioma.
- Epilepsy Surgery in Children: Overview: seizure-outcome surgery for glioneuronal tumors.
- Focal Cortical Dysplasia: the commonest lesion in pediatric epilepsy surgery.
- LITT in Epilepsy Surgery: laser ablation technique and outcomes.
- SEGA: circumscribed astrocytic glioma of TSC.
- Low-Grade Gliomas of the Brainstem in Children: brainstem LGG and targeted therapy.
References
- Wisoff JH, Sanford RA, Heier LA, et al. Primary neurosurgery for pediatric low-grade gliomas: a prospective multi-institutional study from the Children's Oncology Group. Neurosurgery 2011;68(6):1548–1554. doi:10.1227/NEU.0b013e318214a66e. PMID 21368693. verified
- Ryall S, Zapotocky M, Fukuoka K, et al. Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas. Cancer Cell 2020;37(4):569–583.e5. doi:10.1016/j.ccell.2020.03.011. PMID 32289278. verified
- Blumcke I, Spreafico R, Haaker G, et al. Histopathological findings in brain tissue obtained during epilepsy surgery. N Engl J Med 2017;377(17):1648–1656. doi:10.1056/NEJMoa1703784. PMID 29069555. verified
- Bale TA, Rosenblum MK. The 2021 WHO Classification of Tumors of the Central Nervous System: an update on pediatric low-grade gliomas and glioneuronal tumors. Brain Pathol 2022;32(4):e13060. doi:10.1111/bpa.13060. PMID 35218102. verified
- Bonney PA, Glenn CA, Ebeling PA, et al. Seizure freedom rates and prognostic indicators after resection of gangliogliomas: a review. World Neurosurg 2015;84(6):1988–1996. doi:10.1016/j.wneu.2015.06.044. PMID 26123501. verified
- Schindler G, Capper D, Meyer J, et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol 2011;121(3):397–405. doi:10.1007/s00401-011-0802-6. PMID 21274720. verified
- Dahiya S, Haydon DH, Alvarado D, et al. BRAF(V600E) mutation is a negative prognosticator in pediatric ganglioglioma. Acta Neuropathol 2013;125(6):901–910. doi:10.1007/s00401-013-1120-y. PMID 23609006. verified
- Rivera B, Gayden T, Carrot-Zhang J, et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol 2016;131(6):847–863. doi:10.1007/s00401-016-1549-x. PMID 26920151. verified
- Chang EF, Christie C, Sullivan JE, et al. Seizure control outcomes after resection of dysembryoplastic neuroepithelial tumor in 50 patients. J Neurosurg Pediatr 2010;5(1):123–130. doi:10.3171/2009.8.PEDS09368. PMID 20043747. verified
- Huse JT, Snuderl M, Jones DT, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): an epileptogenic neoplasm with oligodendroglioma-like components, aberrant CD34 expression, and genetic alterations involving the MAP kinase pathway. Acta Neuropathol 2017;133(3):417–429. doi:10.1007/s00401-016-1639-9. PMID 27812792. verified
- Ida CM, Johnson DR, Nair AA, et al. Polymorphous low-grade neuroepithelial tumor of the young (PLNTY): molecular profiling confirms frequent MAPK pathway activation. J Neuropathol Exp Neurol 2021;80(9):821–829. doi:10.1093/jnen/nlab075. PMID 34363682. verified
- Ida CM, Rodriguez FJ, Burger PC, et al. Pleomorphic xanthoastrocytoma: natural history and long-term follow-up. Brain Pathol 2015;25(5):575–586. doi:10.1111/bpa.12217. PMID 25318587. verified
- Bandopadhayay P, Ramkissoon LA, Jain P, et al. MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nat Genet 2016;48(3):273–282. doi:10.1038/ng.3500. PMID 26829751. verified
- Pollack IF, Claassen D, al-Shboul Q, et al. Low-grade gliomas of the cerebral hemispheres in children: an analysis of 71 cases. J Neurosurg 1995;82(4):536–547. doi:10.3171/jns.1995.82.4.0536. PMID 7897512. verified
- Englot DJ, Berger MS, Barbaro NM, Chang EF. Factors associated with seizure freedom in the surgical resection of glioneuronal tumors. Epilepsia 2012;53(1):51–57. doi:10.1111/j.1528-1167.2011.03269.x. PMID 21933181. verified
- Bonney PA, Boettcher LB, Conner AK, et al. Review of seizure outcomes after surgical resection of dysembryoplastic neuroepithelial tumors. J Neurooncol 2016;126(1):1–10. doi:10.1007/s11060-015-1961-4. PMID 26514362. verified
- Lassaletta A, Zapotocky M, Mistry M, et al. Therapeutic and prognostic implications of BRAF V600E in pediatric low-grade gliomas. J Clin Oncol 2017;35(25):2934–2941. doi:10.1200/JCO.2016.71.8726. PMID 28727518. verified
- Bouffet E, Hansford JR, Garrè ML, et al. Dabrafenib plus trametinib in pediatric glioma with BRAF V600 mutations. N Engl J Med 2023;389(12):1108–1120. doi:10.1056/NEJMoa2303815. PMID 37733309. verified
- Fangusaro J, Onar-Thomas A, Young Poussaint T, et al. Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. Lancet Oncol 2019;20(7):1011–1022. doi:10.1016/S1470-2045(19)30277-330277-3). PMID 31151904. verified
- Arocho-Quinones EV, Lew SM, Handler MH, et al. Magnetic resonance-guided stereotactic laser ablation therapy for the treatment of pediatric brain tumors: a multiinstitutional retrospective study. J Neurosurg Pediatr 2020;26(1):13–21. doi:10.3171/2020.1.PEDS19496. PMID 32217793. verified
- O'Leary S, Haider MA, Truong N, et al. Stereotactic laser ablation for pediatric central nervous system tumors: a systematic review and meta-analysis of the literature. J Neurosurg Pediatr 2025;36(2):230–243. doi:10.3171/2025.1.PEDS24387. PMID 40344762. verified
- Tovar-Spinoza Z, Choi H. MRI-guided laser interstitial thermal therapy for the treatment of low-grade gliomas in children: a case-series review, description of the current technologies and perspectives. Childs Nerv Syst 2016;32(10):1947–1956. doi:10.1007/s00381-016-3193-0. PMID 27659837. verified
Verification (2026-11-13): each reference's authors, title, journal, volume, pages, DOI and PMID were checked on PubMed. Numbers were checked against the PubMed abstracts.
Caveats:
- Several items are standard teaching rather than findings stated in the cited abstracts:
- the typical imaging appearances (cyst and nodule, "bubbly" DNET, calcified PLNTY, meningeal contact of PXA);
- the frontoparietal cortical site of angiocentric glioma;
- "operate early" as a practice principle (it extrapolates reference 15's epilepsy-duration finding).
- Reference 6 mixed adult and pediatric tumors.
- LITT: the following are standard practice, not drawn from the cited abstracts:
- the deep or eloquent niche;
- biopsy through the same trajectory;
- steroids for edema;
- the LEAT seizure-outcome caveat.
- References 20–22 include pilocytic astrocytomas, SEGAs and some high-grade tumors, not only supratentorial LGG.
- The DNET and ganglioglioma seizure series include adults.
- The figure is an original schematic.